Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

Huang, Yan; Qi, Min; Liao, Cheng-Jin; Xun, Jinrui; Zou, Jiong; Huang, Haiyue; Long, Liyuan; Chen, Jun; Fan, Xue‐Gong; Chen, Ruochan

doi:10.1007/s40121-021-00511-w

Cited by 7 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published European study showed that 24-week HBsAg decline during PegIFNα-based treatment was superior to 12-week HBsAg decline for predicting subsequent HBsAg loss [23], which was confirmed in the present study. In addition, this study confirmed the conclusion that the lower the baseline HBsAg level, the higher the functional cure rate, as reported previously [12,13,24–27].…”

Section: Discussionsupporting

confidence: 92%

The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers

Ning

Peng

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Objectives Pegylated interferon α-2b (PegIFNα-2b) therapy can help inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) achieve clinical cure. To explore and compare the efficacy, safety, and relevant influential factors of PegIFNα-2b monotherapy and PegIFNα-2b-based immunotherapy for IHCs. Methods This exploratory, prospective, single-center, randomized controlled trial enrolled 40 IHCs who were randomized into group A (PegIFNα-2b treatment for 68 weeks) and group B (two cycles of PegIFNα-2b treatment with a lead-in period of GM-CSF and vaccine treatment before each cycle). The primary endpoint was 68-week HBsAg loss rate. Results At week 68, the HBsAg loss rates were 45.45% [full analysis set (FAS)] and 46.67% [per-protocol set (PPS)]. There was no statistically significant difference in HBsAg loss rate between groups A and B (P > 0.05). Univariate analysis revealed that age ≤40 years old, baseline HBsAg <200 IU/ml, and 24-week HBsAg decline ≥2 log10 IU/ml were significantly associated with HBsAg loss in FAS population (P < 0.05). Multivariate analysis showed that only 24-week HBsAg decline ≥2 log10 IU/ml was the independent influencing factor in both FAS and PPS populations (P < 0.05). The adverse events were common and mild, and the therapies were well-tolerated. Conclusion Treatment of IHCs with PegIFNα-2b-based therapy could result in a high HBsAg loss rate. The HBsAg loss rate of combined immunotherapy was similar to that of PegIFNα-2b monotherapy, and the safety was good. ClinicalTrials.gov ID: NCT05451420.

show abstract

Section: Discussionsupporting

confidence: 92%

The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers

Ning

Peng

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…After final screening, 12 articles were excluded, i.e., one article with a small sample size, three articles with incomplete outcome data, two articles with the same cohort, and six articles with baseline HBsAg <1500 IU/mL but not in compliance with one or more IHC criteria. Finally, a total of 11 articles were included in this meta-analysis (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21).…”

Section: Resultsmentioning

confidence: 99%

“…All 11 studies were conducted in Asia, including 10 in China and one in Singapore ( 13 ). Seven articles were published in English ( 11 – 15 , 20 , 21 ) and four in Chinese ( 16 – 19 ). The baseline HBsAg levels were <20 IU/mL in two studies ( 14 , 16 ), <100 IU/mL in one study ( 12 ), <1000 IU/mL in six studies ( 11 , 13 , 17 , 18 , 20 , 21 ), and <1500 IU/mL in two studies ( 15 , 19 ).…”

Section: Resultsmentioning

confidence: 99%

“…Seven articles were published in English ( 11 – 15 , 20 , 21 ) and four in Chinese ( 16 – 19 ). The baseline HBsAg levels were <20 IU/mL in two studies ( 14 , 16 ), <100 IU/mL in one study ( 12 ), <1000 IU/mL in six studies ( 11 , 13 , 17 , 18 , 20 , 21 ), and <1500 IU/mL in two studies ( 15 , 19 ). Ten studies used Peg-IFN treatment, with NA treatment (n=1) or no treatment (n=9) in the control group.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

BackgroundExpanding antiviral therapy to benefit more populations and optimizing treatment to improve prognoses are two main objectives in current guidelines on antiviral therapy. However, the guidelines do not recommend antiviral therapy for inactive hepatitis B surface antigen (HBsAg) carriers (IHCs). Recent studies have shown that antiviral therapy is effective with good treatment outcomes in IHC populations. We conducted a systematic review and meta-analysis of HBsAg clearance and conversion in IHCs.MethodsWe searched PubMed, Embase, Medline, and Web of Science to retrieve articles on HBsAg clearance in IHCs published between January 2000 and August 2021. Data were collected and analysed using the random-effects model for meta-analysis.ResultsA total of 1029 IHCs from 11 studies were included in this analysis. The overall HBsAg clearance rate was 47% (95% confidence interval (CI): 31% - 64%), with a conversion rate of 26% (95% CI: 15% - 38%) after 48 weeks of Pegylated interferon (Peg-IFN) treatment. In the control group (including nucleos(t)ide analogue (NA) treatment or no treatment), the overall HBsAg clearance rate was only 1.54% (95% CI: 0.56% - 3.00%), which was markedly lower than that in the Peg-IFN group. Further analysis showed that a low baseline HBsAg level and long treatment duration contributed to a higher HBsAg clearance rate.ConclusionThis study showed that treatment of IHCs can be considered to achieve a clinical cure for chronic hepatitis B virus (HBV) infection. After Peg-IFN treatment, the HBsAg clearance rate was 47%, and the conversion rate was 26%, which are markedly higher than those reported by previous studies on Peg-IFN treatment in patients with chronic hepatitis B (CHB). A low baseline HBsAg level and long treatment duration were associated with HBsAg clearance in IHCs. Therefore, antiviral therapy is applicable for IHCs, a population who may be clinically cured.Systematic Review Registrationhttp://www.crd.york.ac.uk/PROSPERO, CRD): CRD42021259889.

show abstract

“…They are also the first cytokines used in therapy ( 33 ). IFNs are used to treat autoimmune diseases including multiple sclerosis ( 34 ), tumors such as lymphoma ( 35 ), infectious diseases such as disseminated nocardiosis ( 36 ), and hepatitis C ( 37 ). Recently, it is even considered as a potential therapeutic target for COVID-19.…”

Section: Ifns and Their Absmentioning

confidence: 99%

Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection

2021

View full text Add to dashboard Cite

Adult-onset immunodeficiency syndrome due to anti-interferon (IFN)-γ autoantibodies has attracted much attention in recent years. It usually occurs in previously healthy people and usually presents as chronic, recurrent, and hard-to-control infections that can be effectively treated with aggressive antibiotic therapy. Adult-onset immunodeficiency syndrome is also referred to as AIDS-like syndrome. Anti-type I IFN (IFN-I) autoantibodies have been reported to play a significant role in the pathogenesis of coronavirus disease 2019 (COVID-19) and preexisting anti-IFN-I autoantibodies are associated with an increased risk of severe COVID-19. This review summarizes the effects of anti-IFN autoantibodies on the susceptibility and severity of various infectious diseases, including SARS-CoV-2 infection. In addition, we discuss the role of anti-IFN autoantibodies in the pathogenesis of autoimmune diseases that are characterized by recurrent infections.

show abstract

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

Cited by 7 publications

References 23 publications

The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers

The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis

Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection

Contact Info

Product

Resources

About